Acasti Pharma Inc

NASDAQ:ACSTUnited States

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

Contact Information

Headquarters

3009 Boul. De La Concorde East, Suite 102LAVAL, QC, Canada H7E 2B5

Phone

450-686-4555

Fax

450-686-2505

Executives

Independent Chairman of the Board

Vimal Kavuru

Chief Executive Officer

Prashant Kohli

Principal Financial Officer, Principal Accounting Officer

Robert Delaversano

Vice President - Clinical Operations

Carrie D'Andrea

Vice President - Program Management

Amresh Kumar